ArticleJournal of cardiothoracic surgery2026
Biventricular impella support in acute antibody-mediated cardiac allograft rejection with severe hemodynamic compromise.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute antibody-mediated cardiac allograft rejection (AMR) can lead to SCAI Stage D cardiogenic shock, frequently necessitating escalation to extracorporeal membrane oxygenation support. However, biventricular Impella (BiPella), configured with Impella 5.5 and Impella RP Flex, may offer an alternative, less invasive cardiac unloading and support. CASE PRESENTATION: We present a 28-year-old male nine-months post-heart transplantation who developed refractory shock from AMR after immunosuppression nonadherence. Hemodynamic instability and elevated filling pressures prompted emergent initiation of simultaneous Impella 5.5 and Impella RP Flex support. Over two weeks, cardiac function improved significantly for BiPella removal and discharge.
conclusionsIn select patients, BiPella may serve as a less invasive alternative to venoarterial extracorporeal membrane oxygenation support in rejection-associated biventricular failure, with potential advantages for substantial ventricular unloading, early mobilization, and bridging to recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.